Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer

Inclusion Criteria

• •Biopsy-documented adenocarcinoma of the prostate which is intermediate or high risk, defined as possessing one or more of the following features:
• •* Gleason \>= 7
• •* \> 50% biopsy cores +
• •* Prostate-specific antigen (PSA) \>= 10
• •Interested in undergoing a radical prostatectomy as definitive management for prostate cancer
• •No clinical or radiographic evidence for distant metastatic disease
• •* In subjects with PSA \< 20 no radiographic staging is required in the absence of clinical symptoms for distant metastatic disease; for those with PSA \> 20, a bone scan must document lack of concern for bone involvement